Cancer-Chronic Myeloid Leukemia

HittPack™

A search of the latest news and medical research findings

October 3, 2011
# Contents

I. Disease and Treatment Information in Chronic Myeloid Leukemia ............................................. 2
   Medscape Medical News (free password required) ................................................................. 2
   MedpageToday ......................................................................................................................... 5
   Reuters Health ....................................................................................................................... 7
II. Recent News Articles in Chronic Myeloid Leukemia ..................................................................... 2
   Medscape Medical News (free password required) ................................................................. 2
   MedpageToday ......................................................................................................................... 5
   Reuters Health ....................................................................................................................... 7
III. Press Releases in Chronic Myeloid Leukemia ........................................................................... 9
   Eurekalert.org ....................................................................................................................... 9
   Newswise.com ...................................................................................................................... 18
   Google.com .......................................................................................................................... 23
IV. US Food and Drug Administration Info on Chronic Myeloid Leukemia ..................................... 24
   Drugs@FDA Database .......................................................................................................... 24
   2011 Advisory Committee Meetings ..................................................................................... 27
V. Guidelines in Chronic Myeloid Leukemia ................................................................................. 27
   National Guidelines Clearinghouse--Guidelines.gov ............................................................ 27
   National Comprehensive Cancer Network ............................................................................. 28
   European Society for Medical Oncology ............................................................................. 29
VI. Conferences and Medical Associations for Chronic Myeloid Leukemia ................................. 29
   Conferences ......................................................................................................................... 29
   Medical Associations .......................................................................................................... 29
VII. Key Opinion Leaders in Chronic Myeloid Leukemia ................................................................. 29
VIII. Clinical Trials in Progress in Chronic Myeloid Leukemia ..................................................... 31
IX. PubMed Search in Chronic Myeloid Leukemia ....................................................................... 37
   Randomized Controlled Trials .......................................................................................... 38
   Reviews ............................................................................................................................... 39
   Editorials ............................................................................................................................. 42
I. Disease and Treatment Information in Chronic Myeloid Leukemia

- **The Leukemia & Lymphoma Society** – Chronic Myeloid Leukemia
- **American Cancer Society** – Leukemia – Chronic Myeloid (CML)
  [http://www.cancer.org/Cancer/Leukemia-ChronicMyeloidCML/index](http://www.cancer.org/Cancer/Leukemia-ChronicMyeloidCML/index)
- **National Cancer Institute** – Chronic Myelogenous Leukemia Treatment (PDQ®)
  Oncologist-approved cancer information from the American Society of Clinical Oncology
- **Mayo Clinic** – Chronic myelogenous leukemia

II. Recent News Articles in Chronic Myeloid Leukemia

**Medscape Medical News (free password required)**

[http://www.medscape.com/] search term = chronic myeloid leukemia; all results for the past year.

- **Azacitidine Effective Against Acute Myeloid Leukemia** Azacitidine effectively treats acute myeloid leukemia (AML) in nearly a third of patients, researchers from Italy report in the July 14th online Cancer. News, Reuters Health Information, August 2011

- **Cenersen Combo May Be Effective in Acute Myeloid Leukemia**... with or without cytarabine, may be effective against refractory or relapsed acute myeloid leukemia (AML), according to the results of a phase II study. News, Reuters Health Information, July 2011

- **Crizotinib Coming Soon for ALK-Positive NSCLC**... to 6,000 patients each year in the United States who are diagnosed with chronic myeloid leukemia and treatable with the targeted agent imatinib ( ... News, Medscape Medical News, July 2011

- **Nilotinib Beats Imatinib at 24 Months in Treatment of CML**... over imatinib for the treatment of newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase, Andreas Hochhaus, MD, told ... News, Medscape Medical News, June 2011
▪ **Faster Response Rates in CML with Bosutinib** In patients newly diagnosed with *chronic myeloid leukemia* (CML), bosutinib treatment resulted in better rates of major molecular response than imatinib. News, Medscape Medical News, June 2011

▪ **Hairy-Cell Leukemia Disease-Defining Mutation Identified** ... for the development of drugs and the understanding of genetic lesions. "*Chronic myeloid leukemia*, acute promyelocytic leukemia, and ALK-positive ... News, Medscape Medical News, June 2011

▪ **Age Does Not Affect Response to Imatinib in CML** Overall survival is similar in older and younger patients with *chronic myeloid leukemia* (CML) who are treated with imatinib. News, Medscape Medical News, March 2011

▪ **CML Patients on Imatinib Live as Long as General Population** Patients with *chronic myelogenous leukemia* (CML) treated with imatinib who remain in complete cytogenetic remission for 2 years have survival rates ... News, Medscape Medical News, March 2011

▪ **Second-Generation TKIs Join Imatinib as Front-Line Treatment for CML** Updated NCCN guidelines for *chronic myelogenous leukemia* (CML) name the second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib as ... News, Medscape Medical News, March 2011

▪ **Fludarabine Plus Rituximab Safe First-Line Treatment for Symptomatic CLL** Rituximab is safe and effective out to nearly 10 years for patients with *chronic lymphocytic leukemia* (CLL), according to new results published online ... News, Reuters Health Information, February 2011


▪ **New Target, Drug Potential Found for Colon Cancer** ... to block SRC function and is already being used to treat patients with *chronic myeloid leukemia*, or CML. "Our findings have revealed two potential new ... News, Reuters Health Information, January 2011

▪ **Dr. Clayton Smith Moves to UPCI From Vancouver** ... that are currently necessary. This has already happened with *chronic myeloid leukemia* (CML), he said. "Ten years ago, CML was treatable ... News, Medscape Medical News, January 2011

▪ **European Union Approves Nilotinib First-Line Therapy for Ph+ CML** ... Commission has approved nilotinib for the first-line treatment of *chronic*-phase Philadelphia chromosome-positive (Ph+) *chronic myeloid leukemia* ... News, Medscape Medical News, January 2011

▪ **Bosutinib: A Fourth Drug for Chronic Myeloid Leukemia** ... end point, bosutinib demonstrated efficacy as a front-line agent in *chronic myeloid leukemia*. It was also effective in patients resistant/intolerant ... News, Medscape Medical News, December 2010
▪ **Durable Efficacy Seen With Nilotinib in CML** ... treatment failures was very low and responses remained stable among patients with chronic myeloid leukemia (CML) receiving nilotinib as first-line therapy. News, Medscape Medical News, December 2010

▪ **Follow-up Results Favor Dasatinib Over Imatinib as CML Front-Line Therapy** ... imatinib (Gleevec; Novartis Oncology) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). The 18-month follow-up data ... News, Medscape Medical News, December 2010

▪ **Rituximab May Reduce Chronic GVDH After Stem Cell Transplantation** Rituximab prophylaxis reduced the appearance of chronic graft-versus-host disease (GVHD) and halved the use of steroids, compared with historic controls. News, Medscape Medical News, December 2010

▪ **TET2 Mutation May Play Role in Development of Acute Myeloid Leukemia** The TET2 gene is found in a broad range of myeloid malignancies; researchers are now identifying the role it plays in the pathologic process. News, Medscape Medical News, December 2010

▪ **Novel Agent Ponatinib Shows Promise in Resistant CML** ... are preliminary, but ponatinib has shown clinical evidence of antileukemic activity in patients with resistant/refractory chronic myeloid leukemia (CML). News, Medscape Medical News, December 2010

▪ **Double Cord Blood Transplant Better Than Single in Leukemia** For patients with leukemia who are in first remission, a double cord blood transplant offers a lower rate of relapse and improved leukemia-free survival. News, Medscape Medical News, December 2010

▪ **New Drugs and Research to Be Discussed at ASH 2010** ... new drug highlighted by Dr. Abrams was ponatinib, which is directed at chronic myeloid leukemia (CML). Although this drug is a tyrosine kinase ... News, Medscape Medical News, December 2010

▪ **2010 Rock Stars of Science Features 6 Cancer Docs** ... Sawyers, who has been part of teams that discovered the groundbreaking chronic myeloid leukemia drug Gleevec (Novartis) and the potentially ... News, Medscape Medical News, December 2010

▪ **Survival After Allogeneic Cell Transplantation Continues to Improve** ... make-up of patients has changed over time. The number of patients with chronic myeloid leukemia who undergo transplantation has declined since the ... News, Medscape Medical News, November 2010

▪ **Major and Notable Cancer Advances in 2010** ... nilotinib (Tasigna) might provide even more effective options against chronic myeloid leukemia than the original tyrosine kinase inhibitor imatinib ( ... News, Medscape Medical News, November 2010

▪ **FDA Approves Dasatinib First-Line Therapy for Chronic Myeloid Leukemia** The FDA has approved an expanded indication for dasatinib for the first-line treatment of chronic-phase Ph+ CML. ... treatment of chronic-phase ... News, Medscape Medical News, October 2010
• **Imatinib May Cure Some CML Patients** ... counter to standard practice -- that imatinib treatment can be stopped in some **chronic myeloid leukemia** (CML) patients. In fact, they might even be cured. News, Medscape Medical News, October 2010

• **CML Patients Had a Higher Risk of Second Malignancies Before Gleevec** Before the advent of imatinib, patients with **chronic myeloid leukemia** (CML) had a high long-term risk of a second primary malignancy and only half survived ... News, Reuters Health Information, October 2010

---

**MedpageToday**

http://www.medpagetoday.com/; search term = leukemia; all results for the past 9 months.

**Conversations with...Susan L. Cohn, MD**

9/11/2011

"Conversations with ..." is a series of exclusive video interviews with leaders of medical research and policy. In this segment, George Lundberg, MD, MedPage Today Editor-at-Large, discusses advances in pediatric oncology with Susan L. Cohn, MD, professor of pediatrics at the University of Chicago’s Pritzker School of Medicine.

---

**Young Ca Survivors Face Lifelong Risk of More Cancers**

6/29/2011

One in 10 childhood cancer survivors faces a lifelong risk of developing at least one subsequent neoplasm, particularly if they were treated with radiation, a large retrospective study has shown.

---

**Single Mutation Key to Hairy Cell Leukemia**

6/11/2011

A single mutation occurred in every patient in a cohort with hairy cell leukemia, suggesting that targeting the mutation could have major

---

**Nilotinib Still Trumps Imatinib in Chronic CML**

8/20/2011

Long-term results from a major clinical trial in chronic myeloid leukemia (CML)

---

**AAN: Case Report Links Cladribine to PML**

4/13/2011

HONOLULU -- A patient treated with cladribine for hairy cell leukemia went on to develop progressive multifocal leukoencephalopathy, suggesting that the drug may pose a similar risk when used in multiple sclerosis, researchers reported here.

---

**Imatinib Normalizes Life Expectancy in CML**

3/25/2011

Patients with chronic myeloid leukemia who respond to initial treatment with imatinib (Gleevec) now have a normal life expectancy,
confirm the superiority of nilotinib (Tasigna) over imatinib (Gleevec), researchers reported.

**Early Promise for CLL Therapy**
8/10/2011

Three patients with refractory chronic lymphocytic leukemia (CLL) have responded following infusion of autologous T-cells with genetically modified antigen receptor, investigators reported.

**Early Life on a Farm Linked to Blood Cancers**
7/29/2011

Children who grow up around livestock are at elevated risk for hematologic cancers in later life, New Zealand researchers found.

**Cancer Risk Higher in Tall Women**


implications for treating the disease, Italian investigators reported.

**ASCO: Methotrexate Boost Improves ALL Outcomes**
6/4/2011

CHICAGO -- There's new life in an old drug for high-risk acute lymphoblastic leukemia (ALL).

**Lab Notes: Bat Spit and Why Negative Campaign Ads Work**
5/20/2011

This week's installment of Lab Notes features a therapy for stroke -- bat saliva -- that once bombed but is being given a second chance, a study that may explain why negative campaign ads work so well, and more.

**MicroRNA Clusters Implicated in CLL**
1/5/2011

A potential clue -- involving MicroRNA clusters -- may help unlock mysteries surrounding the development, clinical course, and perhaps the prognosis of chronic lymphocytic leukemia (CLL), researchers report.

**Cognitive Effects After Stem Cell Transplant Persist**
5/5/2011

The neurocognitive deficits that trouble many cancer

**Combo Toxic but Effective for CML**
12/22/2010

A high induction dose of cytarabine for acute myeloid leukemia may add to toxicity without improving outcomes, researchers found.
Tall women are at greater overall risk for cancer than their short counterparts, although the degree of risk varies depending on the type of cancer, a large U.K. prospective study confirmed.

Transplants with umbilical cord blood or half-matched bone marrow resulted in outcomes comparable to historical results with fully matched tissue, results of two small clinical trials showed.

Adding pegylated interferon alfa-2a to standard therapy for chronic myeloid leukemia significantly improved responses, researchers said.

For one patient with a mysterious form of cancer, the ability to sequence an individual's genome has paid off in the form of improved treatment, researchers said.

Measuring gene expression in leukemic stem cells (LSCs) may have prognostic value for patients with acute myeloid leukemia (AML), researchers found.
... development of imatinib (Novartis's Glivec) and dasatinib (Bristol-Myers Squibb's Sprycel) -- revolutionary, targeted treatments for chronic myeloid leukemia. ...
Wed Sep 21, 2011 7:21am EDT

- **Novartis JAK inhibitor INC424 shows significant clinical benefit** ...
  ... in essential thrombocytemia and agnogenic myeloid metaplasia: an ... events that convert chronic myeloproliferative neoplasms to leukemia. ...
  Sat Jun 4, 2011 2:31pm EDT

- **Novartis highlights extensive data on numerous compounds at ASCO** ...
  ... in patients with myelofibrosis on June 6[1]. In addition, a study of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase ...
  Wed Jun 1, 2011 1:16am EDT

- **Ariad Pharmaceuticals not for sale: CEO**
  ... The company is currently testing ponatinib in a mid-stage trial as a treatment for two types of blood cancers -- chronic myeloid leukemia and Philadelphia ...
  Tue Mar 29, 2011 3:23pm EDT

- **UPDATE 1-Cephalon offers $231 mln takeover of ChemGenex**
  ... company is seeking Food and Drug Administration approval to sell the injectable drug Omapro in the United States for chronic myeloid leukemia patients with a ...
  Mon Mar 28, 2011 8:03pm EDT

- **New target, drug potential found for colon cancer**
  ... finding that led them to look at Sprycel, which is known to block SRC function and is already being used to treat patients with chronic myeloid leukemia, or CML ...
  Mon Jan 31, 2011 4:03pm EST

- **UPDATE 1-BioSante gets orphan status for skin cancer vaccine**
  ... It has already received orphan drug designations for its vaccines to treat pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia. ...
  Tue Jan 25, 2011 8:42am EST

- **UPDATE 1-Bristol-Myers cancer drug receives new approval**
  ... Sprycel received "first-line" approval for a type of leukemia known as Philadelphia chromosome positive chronic phase chronic myeloid leukemia, the US Food and ...
  Thu Oct 28, 2010 1:35pm EDT

- **Glivec study gives hope of cure for some leukemia**
It had been thought that **chronic myeloid leukemia** (CML) would inevitably return if treatment with drugs such as Novartis's Glivec, or imatinib, was discontinued ...
Wed Oct 20, 2010 9:45am EDT

- **Glivec study gives hope of cure for some leukaemia**
  It had been thought that **chronic myeloid leukemia** (CML) would inevitably return if treatment with drugs such as Novartis's Glivec, or imatinib, was discontinued ...
  Tue Oct 19, 2010 7:08pm EDT

### III. Press Releases in Chronic Myeloid Leukemia

**Eurekalert.org**

[www.eurekalert.org; search term = chronic myeloid leukemia; first 30 results.](#)

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>URL</th>
<th>Percentage</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>04 Sep 11</td>
<td>Gene defect that predisposes people to leukemia discovered</td>
<td><a href="http://www.eurekalert.org/pub_releases/2011-09/uow-gdt090211.php">http://www.eurekalert.org/pub_releases/2011-09/uow-gdt090211.php</a></td>
<td>83%</td>
<td></td>
</tr>
<tr>
<td>04 Sep 11</td>
<td>Unconventional hunt for new cancer targets leads to</td>
<td></td>
<td>76%</td>
<td></td>
</tr>
</tbody>
</table>
**powerful drug candidate for leukemia**

... a powerful drug candidate for leukemia ... new potential treatment for acute myeloid leukemia (AML). As reported in Nature ... a therapeutic target in acute myeloid leukemia," appears in Nature online on ...


---

**John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO ..**

... and satisfaction with care among chronic myeloid leukemia patients. " ... Association between chronic myeloid leukemia (CML) treatment responses and patient ... colleagues assessed patients' awareness of chronic myeloid leukemia (CML) treatment response categorizations and ...


---

**Toward a more efficient therapy for a specific form of leukemia**

... Chronic myeloid leukemia (CML) is a particular form ... Chronic myeloid leukemia (CML) ... as viruses and bacteria. In chronic myeloid leukemia, the formation of granulocytes, a ...


---

**Study reveals origins of a cancer affecting the blood and bone marrow**

... origins of a type of myeloid leukemia, a blood cancer that affects ... unexpected role for it in chronic myelomonocytic leukemia (CMML). The study is published ...

11 May 11
myeloid leukemia. Normally, the bone marrow makes ...


New drug shows potential for treatment-resistant leukemia

... shows potential for treatment-resistant leukemia ... drug shows promise for treating leukemia patients who have few other ... the drug, DCC-2036, fights chronic myeloid leukemia (CML) in a mouse model ...


Study reveals no impact of age on outcome in chronic myeloid leukemia patients treated with ...

... of age on outcome in chronic myeloid leukemia patients treated with imatinib ( ... median age at diagnosis for chronic myeloid leukemia (CML) is over 60 years ... of 559 patients with early chronic phase CML (six months or ...


New approach to leukemia chemotherapy -- is a cure in sight?

... Research Council New approach to leukemia chemotherapy -- is a cure in sight? Speaking ... discuss a brand new approach to treating chronic myeloid leukaemia (CML) in which a small number ...

The gene processes that drive acute myeloid leukaemia

... gene processes that drive acute myeloid leukaemia ... in the development of acute myeloid leukaemia ... gene mutation found in acute myeloid leukaemia starts the process of ...


New induced stem cells may unmask cancer at earliest stage

... cells from a patient with chronic myeloid leukaemia, a cancer of the blood ... equation. In the case of chronic myeloid leukaemia and other blood diseases, obtaining ... interfere with a study of chronic myeloid leukaemia" whose abnormalities are also encoded ...


Southampton scientists begin patient trials of new leukemia cancer vaccine

... begin patient trials of new leukemia cancer vaccine ... of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone ... In chronic myeloid leukaemia, current treatment can reduce ...


Activity of certain stem cell genes linked with worse outcomes in acute myeloid leukemia ...

... with worse outcomes in acute myeloid leukaemia patients ... found that patients with acute myeloid leukaemia who had higher activity of ... which indicate that human acute myeloid leukaemia (AML) is driven by self ...
New approaches needed for treating chronic myeloid leukemia

... New approaches needed for treating chronic myeloid leukemia ... Chronic myeloid leukemia (CML) was transformed from a ... TITLE: Human chronic myeloid leukemia stem cells are insensitive to ...


JCI online early table of contents: Dec. 13, 2010

... New approaches needed for treating chronic myeloid leukemia ... Chronic myeloid leukemia (CML) was transformed from a ... TITLE: Human chronic myeloid leukemia stem cells are insensitive to ...


New therapies and gene target advance the treatment and understanding of hard-to-treat ...

... the treatment of acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), and how a new ... 800 mg Daily in Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase ... that the incidence rate of chronic myeloid leukemia (CML), a type of blood ...

Phase I trial indicates ponatinib may thwart most resistant CML...

... Drug also acts against chronic myeloid leukemia with untreatable T135I mutation ... new drug appears to help chronic myeloid leukemia patients who are out of ... had Philadelphia-positive acute lymphoblastic leukemia, three had acute myeloid leukemia and four were divided among ...


Researchers discover key mutation in acute myeloid leukemia...

... discover key mutation in acute myeloid leukemia ... for some patients with acute myeloid leukemia (AML), an aggressive blood cancer ... used laboratory tests of their leukemia cells. More than half of ...


Mutations in single gene predict poor outcomes in adult leukemia...

... may guide treatment for acute myeloid leukemia ... prognosis for patients with acute myeloid leukemia. The discovery suggests... ... woman who died of acute myeloid leukemia (AML) has led researchers at ...


Study gives new hope of a drug cure for some patients with chronic myeloid leukaemia...

... cure for some patients with chronic myeloid leukaemia ... leukaemia Some patients with chronic myeloid leukaemia
Cancer-Chronic Myeloid Leukemia HittPack™

(CML) in complete molecular remission ... the bone marrow that results in chronic myeloid leukaemia). **Molecular ...


**New lab test could identify imatinib resistance**

... the standard of care for chronic myeloid leukemia (CML). ... Novartis, revolutionized the treatment of leukemia when it was approved in ... suitable treatment option for individual chronic myeloid leukaemia patients," said Ohba. "This technique ...


**Intensive chemotherapy may be harmful to most older patients with acute myeloid leukemia**

... most older patients with acute myeloid leukemia (AML) is poor, with a ... most common form of acute leukemia among adults and is a ...


**Protein that predicts prognosis of leukemia patients may also be a therapeutic target**

... Protein that predicts prognosis of leukemia patients may also be a ... predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. ... normal hematopoiesis and promotes aggressive myeloid leukemia" ...

http://www.eurekalert.org/pub_releases/2010-07/wifb-
Second-line CML drug evokes faster response, fewer side effects, pivotal study finds

... as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker ... MD Anderson's Department of Leukemia, presented the findings and is ... improve outcomes for patients with chronic myeloid leukemia," said Kantarjian. ...


Drinking alcohol during pregnancy could lead to acute myeloid leukemia in children

... during pregnancy could lead to acute myeloid leukemia in children IMAGE ... PHILADELPHIA — Although acute myeloid leukemia (AML) is relatively rare in ... no significant association with acute lymphoblastic leukemia. Subscribe ...


Study identifies key cause of chronic leukemia progression

... Study identifies key cause of chronic leukemia progression ... reason why a form of leukemia progresses from its more-treatable ... Institute (OSUCCC-James), indicates that chronic myeloid leukemia (CML) progresses when immature white ...

<table>
<thead>
<tr>
<th>Title</th>
<th>Date</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves ...</td>
<td>06 Jan 10</td>
<td><a href="http://www.eurekalert.org/pub_releases/2010-01/jhmi-jhr010610.php-">http://www.eurekalert.org/pub_releases/2010-01/jhmi-jhr010610.php-</a> 9.6KB - Public Press Releases</td>
</tr>
<tr>
<td>Advances in diagnosing and treating leukemia and myeloproliferative disorders</td>
<td>05 Dec 09</td>
<td></td>
</tr>
</tbody>
</table>

... patients suffering from acute promyelocytic leukemia, **chronic myeloid leukemia**, infant acute lymphoblastic
leukemia, and myelofibrosis that are based ... Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the ... with CML in 2009 (The Leukemia & Lymphoma Society. Chronic Myelogenous Leukemia (CML). Available at: www.leukemia-lymphoma.org/all_mat_toc ...


www.newwise.com; search term = “chronic myeloid leukemia”, sorted by date. Results 1 through 20 of 59

Food and Drugs: Administer Together
University of Chicago Medical Center
2011-09-16
A regulatory bias against taking oral anti-cancer medications with food places patients at risk for an overdose and forces them to flush away costly medicines, argues an authority on cancer-drug dosing. It could be safer, more effective and cost-efficient if the cancer drugs that are better absorbed with food were studied and, when appropriate, prescribed to be taken with food.

Scientists Identify Point of Entry for Deadly Ebola Virus
Whitehead Institute for Biomedical Research
2011-08-23
Using an unusual human cell line of this type, Whitehead Institute researchers and their collaborators performed a genetic screen and identified a protein used by Ebola virus to gain entry into cells and begin replicating. The discovery may offer a new approach for the development of antiviral therapeutics.

Matching Targeted Therapies to Tumor’s Specific Gene Mutations May be Key to Personalized Cancer Treatment
University of Texas M. D. Anderson Cancer Center
2011-06-03
Customizing targeted therapies to each tumor’s molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

New Protein Linked to Alzheimer’s Disease

North Shore-Long Island Jewish Health System

2011-05-24

Scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer’s disease.

Most Patients Recover from ‘Chemo-Brain’ by Five Years After Marrow Or Stem Cell Transplant for Cancer

Fred Hutchinson Cancer Research Center

2011-05-03

Many patients who undergo bone marrow or blood stem cell transplantation to treat blood cancers or a “pre-leukemic” condition called myelodysplasia experience a decline in mental and fine motor skills due to the toll of their disease and its treatment. A new study led by researchers at Fred Hutchinson Cancer Research Center, published in the May 2, 2011 online edition of the Journal of Clinical Oncology, found that overall, these effects are largely temporary and that most patients can expect a return to normal motor and memory function within five years. However, the study also found that deficits in fine motor skills and verbal memory remained for a significant percentage of patients and warrant more attention by health care providers.

Cancer Drug Shows Promise for Treating Scleroderma

Hospital for Special Surgery

2011-03-28

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial.

New Induced Stem Cells May Unmask Cancer at Earliest Stage

University of Wisconsin-Madison

2011-02-03
By coaxing healthy and diseased human bone marrow to become embryonic-like stem cells, a team of Wisconsin scientists has laid the groundwork for observing the onset of the blood cancer leukemia in the laboratory dish.

Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML

University of Texas M. D. Anderson Cancer Center

2010-12-06

A new drug appears to help chronic myeloid leukemia patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported at the 52nd Annual Meeting of the American Society of Hematology.

New Lab Test Could Identify Imatinib Resistance

American Association for Cancer Research (AACR)

2010-07-22

1) Imatinib is the standard of care for chronic myeloid leukemia; 2) Fluorescence resonance energy transfer (FRET) may identify resistance; 3) FRET allows for more accurate treatment management.

Protein Predicts Leukemia Prognosis, May be Therapeutic Target

Whitehead Institute for Biomedical Research

2010-07-08

Researchers at Whitehead Institute and Children’s Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. Diagnosed in an estimated 48,000 new patients annually, leukemia is blood cancer.

Second-Line CML Drug Evokes Faster Response, Fewer Side Effects

University of Texas M. D. Anderson Cancer Center

2010-06-02

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

Vaccine Appears to "Mop Up" Leukemia Cells Gleevec Leaves Behind
Johns Hopkins Medicine

2010-04-02

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

Researchers Say Vaccine Appears to “Mop Up” Leukemia Cells Gleevec Leaves Behind

Johns Hopkins Medicine

2010-01-07

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

Second-line CML Drugs Evoke Faster Response than Front-line Therapy

University of Texas M. D. Anderson Cancer Center

2009-12-07

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

Drug Shows Promise for T315I-Mutated Chronic Myeloid Leukemia

University of Texas M. D. Anderson Cancer Center

2009-12-07

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

FDA Approved Leukemia Drug Shows Promising Activity in Ovarian Cancer Cells

University of California, Los Angeles (UCLA), Health Sciences

2009-11-10
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA’s Jonsson Comprehensive Cancer Center found.

Drug Could Provide First Treatment for Scleroderma

Hospital for Special Surgery

2009-10-14

Investigators at Hospital for Special Surgery have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology.

Paul Marks Prize Recognizes Three Young Cancer Researchers

Memorial Sloan-Kettering Cancer Center

2009-09-22

Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year’s Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.

Finding Key to Cancer Drug Gleevec’s Limitations

University of Michigan Health System

2009-08-05

Researchers have learned why Gleevec helps patients with chronic myeloid leukemia survive longer, but doesn't keep the disease from returning if treatment ends. They are now combining imatinib with other drugs in mice to find ways to sensitize resistant leukemia-initiating cells to imatinib and enhance its power.

Researchers Discover Novel Tumor Suppressor

La Jolla Institute for Allergy and Immunology

2009-08-03
La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia.

Google.com

Search term = “chronic myeloid leukemia press releases”. First 10 results returned

- Downloads | Press Releases of CML Advocates Network | Public ...
  www.cmladvocates.net/index.php?option=com_docman...
  Press Release, 17 Aug 2010: "CML Advocates Network" now connects 51 leukaemia patient groupshot! Tooltip 01/28/2011 Hits: 278. 17 August 2010 · The ...

- International CML Awareness Day - some history and activities ...
  www.cmladvocates.net/index.php?option=com_content...
  5 days ago – It issued a press release on CML Awareness Day which was ...

- CML News From Google
  newcmldrug.com/cml-news.html
  istockAnalyst.com (press release) 27, 2011) - CaNickel Mining Ltd. ("CaNickel" or the "Company") (TSX:CML) is pleased to announce that it has entered into an ...

- CML welcome for Government housing market package
  www.cml.org.uk › Home › Media
  Sep 2, 2008 – You are here: Home > Media > Press releases ... At the same time, the CML urges the government to focus on the mortgage funding markets as ...

- FDA approves Tasigna® for newly diagnosed chronic myeloid ...
  Jun 18, 2010 – Global Media Relations ... View all media releases ... Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase ...

- Press Release: iCMLf Virtual ... - International CML Foundation
  Dec 20, 2010 – Press Release: ASH Annual Meeting, Orlando - 4th December 2010 ... On 4 December 2010 the International Chronic Myeloid Leukemia ...

- Chronic Myeloid Leukemia
  accc-cancer.org › Education
Effective Practices for **Chronic Myeloid Leukemia**. ACCC Releases Final Report: Treating Small-Population Cancers in the Community Setting. Click here to ...

- **Second-line CML Drugs Evoke Faster, Better Front-line Remissions** …
  www.mdanderson.org › Newsroom › MD Anderson News Releases
  Jun 5, 2010 – Two drugs approved for treatment of drug-resistant **chronic myeloid leukemia** provide patients with quicker, better responses as a first therapy ...

- **Evidence to support chronic myeloid leukaemia drugs "very poor"**
  www.nice.org.uk/newsroom/news/ …
  News… Evidence to support **chronic myeloid leukaemia** drugs "very poor" … the use of dasatinib and nilotinib for the treatment of **chronic myeloid leukaemia** in ...

- **Press Release: Department of Defense Chronic Myelogenous** …
  Jan 23, 2004 – Search Awards › Media Center … Home › Media Center › Archived Press Releases for 2004 › 2004 **Chronic Myelogenous Leukemia** Research …

**IV. US Food and Drug Administration Info on Chronic Myeloid Leukemia**

**Drugs@FDA Database**

*Original New Drug Approvals (NDAs and BLAs) by Month; last 3 months listed*


**October 2011**

None

**September 2011**

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUR-WASH (NDA # 022305)</td>
<td>PURIFIED WATER</td>
<td>S</td>
<td>S</td>
<td>NIAGARA PHARMA</td>
<td>09/01/2011</td>
</tr>
</tbody>
</table>
### Cancer-Chronic Myeloid Leukemia HittPack™

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosage Form</th>
<th>Strength</th>
<th>Company Name</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)</strong></td>
<td></td>
<td>4</td>
<td>MATRIX LABS LTD</td>
<td>09/08/2011</td>
</tr>
<tr>
<td><strong>LAMIVUDINE; ZIDOVUDINE (NDA # 201151)</strong></td>
<td></td>
<td>5</td>
<td>CIPLA LIMITED</td>
<td>09/22/2011</td>
</tr>
<tr>
<td><strong>MEMANTINE HYDROCHLORIDE (NDA # 200155)</strong></td>
<td></td>
<td></td>
<td>TORRENT PHARMS</td>
<td>09/27/2011</td>
</tr>
<tr>
<td><strong>CLOBETASOL PROPIONATE (NDA # 201402)</strong></td>
<td></td>
<td></td>
<td>PERRIGO ISRAEL</td>
<td>09/27/2011</td>
</tr>
<tr>
<td><strong>GEMCITABINE HYDROCHLORIDE (NDA # 200795)</strong></td>
<td></td>
<td>3</td>
<td>HOSPIRA INC</td>
<td>08/04/2011</td>
</tr>
<tr>
<td><strong>ROSUVASTATIN ZINC (NDA # 202172)</strong></td>
<td></td>
<td>2</td>
<td>WATSON LABS INC</td>
<td>08/04/2011</td>
</tr>
<tr>
<td><strong>COMPLERA (NDA # 202123)</strong></td>
<td></td>
<td>4</td>
<td>GILEAD SCIENCES INC</td>
<td>08/10/2011</td>
</tr>
<tr>
<td><strong>ZELBORAF (NDA # 202429)</strong></td>
<td></td>
<td>1</td>
<td>HOFFMAN N LA ROCHE</td>
<td>08/17/2011</td>
</tr>
</tbody>
</table>

**August 2011**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosage Form</th>
<th>Strength</th>
<th>Company Name</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE (NDA # 202171)</strong></td>
<td></td>
<td>4</td>
<td>MATRIX LABS LTD</td>
<td>09/08/2011</td>
</tr>
<tr>
<td><strong>LAMIVUDINE; ZIDOVUDINE (NDA # 201151)</strong></td>
<td></td>
<td>5</td>
<td>CIPLA LIMITED</td>
<td>09/22/2011</td>
</tr>
<tr>
<td><strong>MEMANTINE HYDROCHLORIDE (NDA # 200155)</strong></td>
<td></td>
<td></td>
<td>TORRENT PHARMS</td>
<td>09/27/2011</td>
</tr>
<tr>
<td><strong>CLOBETASOL PROPIONATE (NDA # 201402)</strong></td>
<td></td>
<td></td>
<td>PERRIGO ISRAEL</td>
<td>09/27/2011</td>
</tr>
<tr>
<td><strong>GEMCITABINE HYDROCHLORIDE (NDA # 200795)</strong></td>
<td></td>
<td>3</td>
<td>HOSPIRA INC</td>
<td>08/04/2011</td>
</tr>
<tr>
<td><strong>ROSUVASTATIN ZINC (NDA # 202172)</strong></td>
<td></td>
<td>2</td>
<td>WATSON LABS INC</td>
<td>08/04/2011</td>
</tr>
<tr>
<td><strong>COMPLERA (NDA # 202123)</strong></td>
<td></td>
<td>4</td>
<td>GILEAD SCIENCES INC</td>
<td>08/10/2011</td>
</tr>
<tr>
<td><strong>ZELBORAF (NDA # 202429)</strong></td>
<td></td>
<td>1</td>
<td>HOFFMAN N LA ROCHE</td>
<td>08/17/2011</td>
</tr>
<tr>
<td>Drug Name and FDA Appl. #</td>
<td>Active Ingredients</td>
<td>NDA Chem. Type *</td>
<td>Review Classification **</td>
<td>Company</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>ADCETRIS (BLA # 125388)</td>
<td>BRENTUXIMAB VEDOTIN</td>
<td></td>
<td></td>
<td>SEATTLE GENETICS</td>
</tr>
<tr>
<td>ADCETRIS (BLA # 125399)</td>
<td>BRENTUXIMAB VEDOTIN</td>
<td></td>
<td></td>
<td>SEATTLE GENETICS</td>
</tr>
<tr>
<td>FIRAZYR (NDA # 022150)</td>
<td>ICATIBANT ACETATE</td>
<td>1</td>
<td>P</td>
<td>SHIRE ORPHAN THERAP</td>
</tr>
<tr>
<td>NUCYNTA ER (NDA # 200533)</td>
<td>TAPENTADOL HYDROCHLORIDE</td>
<td>3</td>
<td>S</td>
<td>ORTHO MCNEIL JANSSEN</td>
</tr>
<tr>
<td>XALKORI (NDA # 202570)</td>
<td>CRIZOTINIB</td>
<td>1</td>
<td>P</td>
<td>PFIZER</td>
</tr>
</tbody>
</table>

### July 2011

<table>
<thead>
<tr>
<th>Drug Name and FDA Appl. #</th>
<th>Active Ingredients</th>
<th>NDA Chem. Type *</th>
<th>Review Classification **</th>
<th>Company</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARCAPTA NEOHALER (NDA # 022383)</td>
<td>INDACATEROL MALEATE</td>
<td>1</td>
<td>S</td>
<td>NOVARTIS</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>XARELTO (NDA # 022406)</td>
<td>RIVAROXABAN</td>
<td>1</td>
<td>S</td>
<td>JOHNSON AND JOHNSON</td>
<td>07/01/2011</td>
</tr>
<tr>
<td>BRILINTA (NDA # 022433)</td>
<td>TICAGRELOR</td>
<td>1</td>
<td>S</td>
<td>ASTRAZENECA LP</td>
<td>07/20/2011</td>
</tr>
<tr>
<td>HEPARIN SODIUM (NDA # 201370)</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>PFIZER</td>
<td>07/21/2011</td>
</tr>
<tr>
<td>HEPARIN SODIUM PRESERVATIVE FREE</td>
<td>HEPARIN SODIUM</td>
<td>5</td>
<td>S</td>
<td>PFIZER</td>
<td>07/21/2011</td>
</tr>
</tbody>
</table>
V. Guidelines in Chronic Myeloid Leukemia

National Guidelines Clearinghouse--Guidelines.gov

www.guidelines.gov; Search criteria = chronic myeloid leukemia, all years, sorted by date, 1 to 9 of 9 results listed

   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)

2. The prophylactic use of filgrastim in patients with hematological malignancies. 2009 Sep 23. NGC:007885
   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
3. **Stem cell transplantation in adults: recommendations.** 2009 Jan. NGC:007225
   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. [View all guidelines by the developer(s)]

   Children's Oncology Group - Medical Specialty Society. [View all guidelines by the developer(s)]

   Children's Oncology Group - Medical Specialty Society. [View all guidelines by the developer(s)]

   National Institutes of Health (NIH) Consensus Development Panel on Sickle Cell Disease - Independent Expert Panel; Office of Medical Applications of Research (NIH) - Federal Government Agency [U.S.]. [View all guidelines by the developer(s)]

   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. [View all guidelines by the developer(s)]

8. **Recommendations for the management of BCR-ABL-positive chronic myeloid leukaemia.** 2007. NGC:006175
   British Committee for Standards in Haematology - Professional Association. [View all guidelines by the developer(s)]

   Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. [View all guidelines by the developer(s)]

---

**National Comprehensive Cancer Network**

Free password required

[www.nccn.org](http://www.nccn.org)

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in Chronic Myelogenous Leukemia

**European Society for Medical Oncology**

[www.esmo.org](http://www.esmo.org)

*Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up*

http://annonc.oxfordjournals.org/content/21/suppl_5/v165.full

---

### VI. Conferences and Medical Associations for Chronic Myeloid Leukemia

**Conferences**

- **International Chronic Myeloid Foundation (iCMLf) Conferences** [http://www.cml-foundation.org/meetings](http://www.cml-foundation.org/meetings)
- **Annual European Society of Medical Oncology (ESMO) Congress** [http://www.esmo.org/](http://www.esmo.org/)
- **European School of Haematology (ESH) Conferences** [http://www.esh.org/conferences/](http://www.esh.org/conferences/)
- **American Society of Hematology (ASH)** [http://hematology.org/Meetings/Annual-Meeting/](http://hematology.org/Meetings/Annual-Meeting/)

**Medical Associations**

- **American Association for Cancer Research (AACR)**
- **American Cancer Society (ACS)**
- **American Institute for Cancer Research (AICR)**
- **American Society of Clinical Oncology (ASCO)**
- **American Society of Hematology (ASH)**
- **The Leukemia & Lymphoma Society (LLS)**

---

### VII. Key Opinion Leaders in Chronic Myeloid Leukemia

A listing of key opinion leaders (KOLs) in Chronic Myeloid Leukemia who have participated in recent CME activities available online. Where possible, the sponsor information has been listed.

- **Maurie Markman, MD**, Vice President for Medical Oncology Services, National Director for Medical Oncology, Cancer Treatment Centers of America. Disclosure: Eli Lilly Honoraria Speaking
and teaching; Consulting fee from or consultant for: Genentech, Cellgene, Hana Pharmaceuticals, Boehringer Ingelheim, Ortho Biotech, Morphotech Consulting, Amgen

- **Hagop M. Kantarjian, MD**, Chairman, Department of Leukemia, Professor of Medicine, The University of Texas M.D. Anderson Cancer Center Houston, Texas. Hagop M. Kantarjian, MD, has reported receiving grant support from MGI Pharma, BMS, and Novartis.

- **Jorge E. Cortes, MD**, Professor of Medicine, Deputy Chair, Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, Texas. Jorge Cortes, MD, has reported receiving grant support from BMS and Novartis.

- **Elias J. Jabbour, MD**, Assistant Professor, Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, Texas. Disclosure: Elias J. Jabbour, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.

- **Srdan Verstovsek, MD, PhD**, Associate Professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. Disclosure: Srdan Verstovsek, MD, PhD, has disclosed the following relevant financial relationships: Received grants for clinical research from: Incyte Corporation; Roche; AstraZeneca Pharmaceuticals LP; Celgene Corporation; SBIO, Inc.; Exelixis, Inc.; Eli Lilly and Company; Schering-Plough Corporation; Geron Corp; Cephalon, Inc.

- **Patricia S. Ault, MSN, RN**, Nurse Practitioner, Department of Symptom Research, MD Anderson Cancer Center, Houston, Texas. Disclosure: Patricia S. Ault, MSN, RN, has disclosed the following relevant financial relationships: Served as a speaker or a member of a speakers bureau for: Novartis Pharmaceuticals Corporation

- **Moshe Talpaz, MD**, Professor, Department of Internal Medicine—Hematology/Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan. Moshe Talpaz, MD, has received grant/research support from Ariad Pharmaceuticals, Inc, Bristol-Myers Squibb, Exelixis Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Novartis Pharmaceuticals Corporation.

- **Michael J. Mauro, MD**, Associate Professor, Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. Michael J. Mauro, MD, has received grant/research support from Bristol-Myers Squibb, Merck & Co, Inc, and Novartis Pharmaceuticals Corporation; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is on the advisory board of Novartis Pharmaceuticals Corporation.

- **Neil P. Shah, MD, PhD**, Assistant Professor, Division of Hematology/Oncology, University of California San Francisco School of Medicine, San Francisco, California. Neil P. Shah, MD, PhD, is consultant for Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation.

- **Francis J. Giles, MB, MD, FRCPI, FRCPATH**, Professor of Medicine Chief, Division of Hematology and Medical Oncology University of Texas Health Science Center at San Antonio. Director and AT&T Chair, Institute for Drug Development Cancer Therapy & Research Center San Antonio, Texas. Research support from Amgen, Bristol-Myers Squibb, Merck, Novartis, and Pfizer.
VIII. Clinical Trials in Progress in Chronic Myeloid Leukemia

clinicaltrials.gov

Search criteria- “chronic myeloid leukemia” | Open Studies | Exclude Unknown | Phase III, IV

20 of 20 studies listed

<table>
<thead>
<tr>
<th>Rank</th>
<th>Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients</td>
</tr>
<tr>
<td></td>
<td>Condition: Chronic Myeloid Leukemia</td>
</tr>
<tr>
<td></td>
<td>Intervention: Drug: Nilotinib</td>
</tr>
<tr>
<td>2</td>
<td>Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia</td>
</tr>
<tr>
<td></td>
<td>Condition: Leukemia</td>
</tr>
<tr>
<td></td>
<td>Interventions: Biological: recombinant interferon alfa; Drug: cytarabine; Drug: hydroxyurea; Drug: imatinib mesylate; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation</td>
</tr>
<tr>
<td>3</td>
<td>Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response</td>
</tr>
</tbody>
</table>
|      | Conditions: Philadelphia Chromosome Positive; Chronic Myelogenous Leukemia in Chronic Phase
**Intervention:** Drug: Nilotinib

4  **CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib**

Condition: Chronic Myelogenous Leukemia in Chronic Phase

**Intervention:** Drug: nilotinib

5  **Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation and Optimisation**

Condition: Chronic Myelogenous Leukemia (CML)

**Intervention:** Other: compliance supporting measures

6  **STI571 Prospective Randomized Trial: SPIRIT**

Condition: Chronic Myeloid Leukemia

**Intervention:** Drug: Imatinib mesylate 400 mg; Drug: Imatinib mesylate 600 mg; Drug: Imatinib 400 mg + Peg-Interferon; Drug: Imatinib mesylate 400 mg + Cytarabine

7  **Suboptimal Study Comparing Nilotinib and Imatinib**

Condition: Chronic Myelogenous Leukemia

**Intervention:** Drug: nilotinib; Drug: imatinib

8  **Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and/or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase**

Condition: Leukemia, Myeloid

**Intervention:** Drug: Nilotinib

9  **Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy**

Conditions: Hematologic Malignancies; Acute Myeloid Leukemia; Lymphoid Leukemia; Chronic
Cancer-Chronic Myeloid Leukemia; Hodgkin's Disease; Non-Hodgkin's Lymphoma; Myelodysplastic Syndromes

**Intervention:** Drug: StemEx®

10 **Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib**

Condition: Chronic Myeloid Leukemia

**Intervention:** Drug: Nilotinib, Imatinib

11 **Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial**

Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasms; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific

**Intervention:** Other: educational intervention

12 **Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer**

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Nonmalignant Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific

**Interventions:** Biological: anti-thymocyte globulin; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: fludarabine phosphate; Drug: melphalan; Drug: thiotepa; Radiation: total-body irradiation

13 **Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain**

Condition: Cancer
Interventions: Drug: ketamine hydrochloride; Other: pharmacogenomic studies; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment

14 Stress Management Intervention for Caregivers of Patients Undergoing Bone Marrow Transplant

Conditions: Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor

Interventions: Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: survey administration; Procedure: psychosocial assessment and care; Procedure: stress management therapy; Procedure: support group therapy

15 Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases

Conditions: Leukemia; Myelodysplastic Syndromes

Intervention: Procedure: allogeneic bone marrow transplantation

16 PRO#1278: Fludarabin and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Conditions: Myeloid Malignancies; Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndrome

Interventions: Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose); Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (TBI)

17 Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome; NK Cell Lymphoblastic Leukemia

Interventions: Biological: Single Cord Blood Unit Transplantation; Biological: Double Cord Blood Unit Transplantation
18 **Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation**

**Condition:** Hematologic Malignancies

**Interventions:** Biological: Anti-Thymocyte Globulin (Rabbit); Other: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)

19 **Tasigna in Glivec-resistant or Intolerant Patients in CML**

**Conditions:** CML; Nilotinib; Imatinib Resistant; Imatinib Intolerant

**Intervention:** Drug: nilotinib

20 **Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)**

**Conditions:**
Leukemia, Myelocytic, Acute; Leukemia, Lymphocytic, Acute; Leukemia, Myeloid, Chronic; Myelodysplastic Syndromes

**Interventions:** Drug: Tacrolimus/methotrexate; Drug: Tacrolimus/sirolimus

21 **Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)**

**Conditions:**
GVHD; Adult Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndrome

**Interventions:** Biological: Anti-human-T-lymphocyte Immune Globulin, Rabbit; Biological: Placebo

22 **Chronic Graft-Versus-Host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-Identical Siblings in Patients With Acute Leukemia**

**Conditions:** Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia

**Intervention:** Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin)

23 **Unrelated Double Umbilical Cord Blood Units Transplantation**
Conditions:  
Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute; Leukemia, Myeloid, Chronic  

Intervention: Drug: Stem cell Transplantation

24 Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)  
Condition: Leukemia, Myelocytic, Acute  
Interventions:  
Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Busulfan and Cyclophosphamide (Bu/Cy); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)

25 Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia  
Condition: Acute Myeloid Leukemia  
Intervention: Procedure: Reduced Intensity Conditioning Stem Cell Transplantation

26 Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts  
Conditions: Myelodysplastic Syndromes; MDS; RAEB; Chronic Myelomonocytic Leukemia  
Intervention: Drug: ON 01910.Na

27 Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior AlloHSCT in AML  
Condition: Acute Myeloid Leukemia (AML)  
Interventions: Drug: Busulphan plus Cyclophosphamide; Drug: Busulphan plus Fludarabine

28 Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Conditions:
Leukemia, Myelogenous, Chronic; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute; Myeloproliferative-Myelodysplastic Diseases; Lymphoma, Malignant

Interventions: Drug: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients; Drug: Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies; Other: Hematopoietic Progenitor Cell Transplantation (HPCT); Radiation: CNS radiation treatment for ALL with prior CNS disease patients

29 Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related Haploidentical Donor

Conditions:
Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders

Intervention: Biological: Donor lymphocyte preparation depleted of host functional alloreactive T-cells

30 Darbepoetin Alfa in Anemic Low or Intermediate-1 Risk MDS Subjects

Condition: MDS

Interventions: Drug: Darbepoetin alfa; Drug: Placebo

31 Busulfan and Cyclophosphamide Instead of Total Body Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)

Conditions:
Acute Leukemias; Chronic Leukemias; Myelodysplastic Syndrome; Juvenile Myelomonocytic Leukemia

Intervention: Drug: Busulfan/Cyclophosphamide

IX. PubMed Search in Chronic Myeloid Leukemia
Search = “chronic myeloid leukemia” or “chronic myelogenous leukemia”, published in the last 180 days or 1 year, English only

**Randomized Controlled Trials**

**Results:** 7 (last 1 year)

   Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.
   PMID: 21524239 [PubMed - indexed for MEDLINE]
   Related citations

2. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
   PMID: 21523338 [PubMed - indexed for MEDLINE]
   Related citations

3. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
   PMID: 21422420 [PubMed - indexed for MEDLINE]
   Related citations

4. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
   Related citations
5. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. 
PMID: 20946966 [PubMed - indexed for MEDLINE] 
Related citations

6. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. 
PMID: 20886606 [PubMed - indexed for MEDLINE] 
Related citations

PMID: 20679528 [PubMed - indexed for MEDLINE] 
Related citations

Reviews

Results: 16 (last 180 days)

1. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis. 
PMID: 21761431 [PubMed - indexed for MEDLINE] 
Related citations
2. **Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.**
   Wong M, Sade S, Gilbert M, Klieb HB.
   PMID: 21635826 [PubMed - indexed for MEDLINE] [Free Article]
   Related citations

3. **BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.**
   PMID: 21562040 [PubMed - indexed for MEDLINE]
   Related citations

4. **Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.**
   Breccia M, Alimena G.
   PMID: 21528941 [PubMed - indexed for MEDLINE]
   Related citations

5. **Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.**
   Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM.
   PMID: 21509757 [PubMed - indexed for MEDLINE]
   Related citations

6. **Predicting the response of CML patients to tyrosine kinase inhibitor therapy.**
   White DL, Hughes TP.
   PMID: 21448598 [PubMed - indexed for MEDLINE]
   Related citations

7. **ABL1 fusion genes in hematological malignancies: a review.**
   De Braekeleer E, Douet-Guilbert N, Rowe D, Bown N, Morel F, Berthou C, Férec C, De Braekeleer M.
8. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. 
Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé H, Chen Z. 
PMID: 21422471 [PubMed - indexed for MEDLINE] 
Related citations

9. Interpretation of cytogenetic and molecular results in patients treated for CML. 
Vigil CE, Griffiths EA, Wang ES, Wetzler M. 
PMID: 21419537 [PubMed - indexed for MEDLINE] 
Related citations

10. Tyrosine kinase inhibitors, pancreatic hyperenzymemia and acute pancreatitis: a review. 
Pezzilli R, Fabbri D, Imbrogno A, Corinaldesi R. 
Recent Pat Inflamm Allergy Drug Discov. 2011 May;5(2):165-8. Review. 
PMID: 21413925 [PubMed - indexed for MEDLINE] 
Related citations

11. The renaissance of interferon therapy for the treatment of myeloid malignancies. 
Kiladjian JJ, Mesa RA, Hoffman R. 
PMID: 21389325 [PubMed - indexed for MEDLINE] 
Related citations

12. In search of CML stem cells' deadly weakness. 
Pellicano F, Sinclair A, Holyoake TL. 
PMID: 21373837 [PubMed - indexed for MEDLINE] 
Related citations

Branford S, Prime J. 
PMID: 21360071 [PubMed - indexed for MEDLINE]
Related citations

Petersen C.
PMID: 21336995 [PubMed - indexed for MEDLINE]
Related citations

15. New drugs for chronic myelogenous leukemia.
Santos FP, Quintás-Cardama A.
PMID: 21327563 [PubMed - indexed for MEDLINE]
Related citations

16. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?
von Mehren M, Widmer N.
PMID: 21078547 [PubMed - indexed for MEDLINE]
Related citations

Editorials

Results: 7 (last 1 year)

1. Bringing prognostic scores for chronic myeloid leukemia patients up to date.
Breccia M, Alimena G.
Related citations

2. Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
Mukhopadhyay A, Helgason GV, Karvela M, Holyoake TL.
Related citations

3. Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Stein BL, Smith BD.
PMID: 21782241 [PubMed - in process]
Related citations

4. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
   Smith BD.
   PMID: 21422404 [PubMed - indexed for MEDLINE]
   Related citations

   Mathisen MS, Kantarjian HM, Cortes J, Jabbour E.

6. Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
   Tefferi A.
   PMID: 21210471 [PubMed - indexed for MEDLINE]
   Related citations

7. Can we distinguish chronic myeloid leukemia presenting in the lymphoblastic phase from de novo Philadelphia-positive acute lymphoid leukemia?
   Takahashi N.